The Applications of CRISPR/Cas-mediated Genome Editing in Genetic Hearing Loss

Overview

Journal Cell Biosci

Publisher Biomed Central

Specialty Biology

Date 2023 May 20

PMID 37210555

Authors

Junhao Wu

Yong Tao

Di Deng

Zhaoli Meng

Yu Zhao

Affiliations

Soon will be listed here.

Abstract

Hearing loss (HL) can be caused by a number of different genetic factors. Non-syndromic HL refers that HL occurs as an isolated symptom in an individual, whereas syndromic HL refers that HL is associated with other symptoms or abnormalities. To date, more than 140 genes have been identified as being associated with non-syndromic HL, and approximately 400 genetic syndromes can include HL as one of the clinical symptoms. However, no gene therapeutic approaches are currently available to restore or improve hearing. Therefore, there is an urgent necessity to elucidate the possible pathogenesis of specific mutations in HL-associated genes and to investigate the promising therapeutic strategies for genetic HL. The development of the CRISPR/Cas system has revolutionized the field of genome engineering, which has become an efficacious and cost-effective tool to foster genetic HL research. Moreover, several in vivo studies have demonstrated the therapeutic efficacy of the CRISPR/Cas-mediated treatments for specific genetic HL. In this review, we briefly introduce the progress in CRISPR/Cas technique as well as the understanding of genetic HL, and then we detail the recent achievements of CRISPR/Cas technique in disease modeling and therapeutic strategies for genetic HL. Furthermore, we discuss the challenges for the application of CRISPR/Cas technique in future clinical treatments.

Citing Articles

Advanced Omics Techniques for Understanding Cochlear Genome, Epigenome, and Transcriptome in Health and Disease.

Tisi A, Palaniappan S, Maccarrone M Biomolecules. 2023; 13(10).

PMID: 37892216 PMC: 10605747. DOI: 10.3390/biom13101534.

References

Pickar-Oliver A, Gersbach C . The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20(8):490-507. PMC: 7079207. DOI: 10.1038/s41580-019-0131-5. View

Kim H, Kim J . A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014; 15(5):321-34. DOI: 10.1038/nrg3686. View

Ming M, Ren Q, Pan C, He Y, Zhang Y, Liu S . CRISPR-Cas12b enables efficient plant genome engineering. Nat Plants. 2020; 6(3):202-208. DOI: 10.1038/s41477-020-0614-6. View

Strecker J, Jones S, Koopal B, Schmid-Burgk J, Zetsche B, Gao L . Engineering of CRISPR-Cas12b for human genome editing. Nat Commun. 2019; 10(1):212. PMC: 6342934. DOI: 10.1038/s41467-018-08224-4. View

Li S, Cheng Q, Liu J, Nie X, Zhao G, Wang J . CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA. Cell Res. 2018; 28(4):491-493. PMC: 5939048. DOI: 10.1038/s41422-018-0022-x. View

Deveau H, Garneau J, Moineau S . CRISPR/Cas system and its role in phage-bacteria interactions. Annu Rev Microbiol. 2010; 64:475-93. DOI: 10.1146/annurev.micro.112408.134123. View

Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G . Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25(2):229-233. DOI: 10.1038/s41591-018-0327-9. View

Lu Y, Zhang M, Wei Q, Chen Z, Xing G, Yao J . Disruption of Gprasp2 down-regulates Hedgehog signaling and leads to apoptosis in auditory cells. Biochem Biophys Res Commun. 2021; 574:1-7. DOI: 10.1016/j.bbrc.2021.08.034. View

Song J, Feng Y, Acke F, Coucke P, Vleminckx K, Dhooge I . Hearing loss in Waardenburg syndrome: a systematic review. Clin Genet. 2015; 89(4):416-425. DOI: 10.1111/cge.12631. View

10.

Kurima K, Peters L, Yang Y, Riazuddin S, Ahmed Z, Naz S . Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. Nat Genet. 2002; 30(3):277-84. DOI: 10.1038/ng842. View

11.

Kleinstiver B, Pattanayak V, Prew M, Tsai S, Nguyen N, Zheng Z . High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016; 529(7587):490-5. PMC: 4851738. DOI: 10.1038/nature16526. View

12.

Kleinstiver B, Sousa A, Walton R, Tak Y, Hsu J, Clement K . Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol. 2019; 37(3):276-282. PMC: 6401248. DOI: 10.1038/s41587-018-0011-0. View

13.

Wiles M, Qin W, Cheng A, Wang H . CRISPR-Cas9-mediated genome editing and guide RNA design. Mamm Genome. 2015; 26(9-10):501-10. PMC: 4602062. DOI: 10.1007/s00335-015-9565-z. View

14.

Lovell J, Harper G . The morphology of the inner ear from the domestic pig (Sus scrofa). J Microsc. 2007; 228(Pt 3):345-57. DOI: 10.1111/j.1365-2818.2007.01852.x. View

15.

Zhong Z, Zhang Y, You Q, Tang X, Ren Q, Liu S . Plant Genome Editing Using FnCpf1 and LbCpf1 Nucleases at Redefined and Altered PAM Sites. Mol Plant. 2018; 11(7):999-1002. DOI: 10.1016/j.molp.2018.03.008. View

16.

Leung R, Cheng Q, Wu Z, Khan G, Liu Y, Xia H . CRISPR-Cas12-based nucleic acids detection systems. Methods. 2021; 203:276-281. DOI: 10.1016/j.ymeth.2021.02.018. View

17.

Ran F, Cong L, Yan W, Scott D, Gootenberg J, Kriz A . In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520(7546):186-91. PMC: 4393360. DOI: 10.1038/nature14299. View

18.

Yan W, Hunnewell P, Alfonse L, Carte J, Keston-Smith E, Sothiselvam S . Functionally diverse type V CRISPR-Cas systems. Science. 2018; 363(6422):88-91. PMC: 11258546. DOI: 10.1126/science.aav7271. View

19.

Li W, Feng Y, Chen A, Li T, Huang S, Liu J . Elmod3 knockout leads to progressive hearing loss and abnormalities in cochlear hair cell stereocilia. Hum Mol Genet. 2019; 28(24):4103-4112. PMC: 7305813. DOI: 10.1093/hmg/ddz240. View

20.

Walsh T, Walsh V, Vreugde S, Hertzano R, Shahin H, Haika S . From flies' eyes to our ears: mutations in a human class III myosin cause progressive nonsyndromic hearing loss DFNB30. Proc Natl Acad Sci U S A. 2002; 99(11):7518-23. PMC: 124268. DOI: 10.1073/pnas.102091699. View